Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 465-472

  van Herendael, Hugo ^a   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Amiodarone; Unstable ventricular tachycardia; Ventricular fibrillation

Indexed keywords

ADRENALIN; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BRETYLIUM; DIGOXIN; DILTIAZEM; DRONEDARONE; LIDOCAINE; METOPROLOL; PLACEBO; PROCAINAMIDE; SIMVASTATIN; SOTALOL; WARFARIN; ANTIARRHYTHMIC AGENT;

ANOREXIA; ANTIARRHYTHMIC ACTIVITY; ATAXIA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIOVENTRICULAR NODE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOTHYROIDISM; LIVER FUNCTION; LUNG FIBROSIS; NAUSEA; NIGHTMARE; PARESTHESIA; REVIEW; RISK REDUCTION; SIDE EFFECT; SINUS BRADYCARDIA; SKIN DISCOLORATION; SKIN SENSITIVITY; THROMBOPHLEBITIS; TORSADE DES POINTES; TREMOR; VISUAL DISORDER; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 79952054595     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Singh BN. Amiodarone: Historical development and pharmacologic profile. Am Heart J. 1983;106:788-797.
2. Van Schepdael J, Solvay H: Etude Clinique De L'Amiodarone Dans Les Troubles du Rhythme Cardiaque. Presse Med. 1970;78:1849.
3. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970;39(4):657-667.
4. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976;38(7):934-944.
5. Connolly SJ. Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation. 1999;100(19):2025-2034.
6. Andreasen F, Agerback H, Bjerregaard P, Gotzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol. 1981;19(4):293-299.
7. HoIt DW, Tucker CT, Jackson PR, Storey CGA. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840-847.
8. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin. Pharmacol. 1991;31:1061
9. Anastasiou-Nana M, Lewis G, Moulopoulos S. Plasma levels of amiodarone after intravenous and oral administration. J Clin Chem Clin Biochem. 1981;19:599-600.
10. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol. 1999;84(9A): 37R-45R.
11. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35(1):13-29.
12. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol. 1970;39:668-674.
13. Morady F, DiCarlo LA Jr, Krol RB, Baerman JM, de Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol. 1986;7(1):148-157.
14. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 1993;88(3):1063-1071.
15. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341(12):871-878.
16. Dorian P, Cass D, Shwartz B, et al; Amiodarone as compared with lidocaine for shock resistant ventricular fibrillation. N Engl J Med. 2002;346(12):884-890.
17. Marill KA, deSouza IS, Nishijima DK, et al. Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Ann Emerg Med. 2006;47(3):217-224.
18. Tomlinson DR, Cherian P, Betts TR, Bashir Y. Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment? Emerg Med J. 2008;25(1):15-18.
19. Schutzenberger W, Leisch F, Kerschner K, Harringer W, Herbinger W. Clinical efficacy of intravenous amiodarone in the short-term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J. 1989;62(5):367-371.
20. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, Wellens HJ. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78(1):43-46.
21. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92(11):3264-3272.
22. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996;27(1):67-75.
23. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995;92(11):3255-3263
24. Nägele H, Behrens S, Castel A. Ventricular tachycardia and aggravation of Brugada ECG pattern in a patient with coronary artery disease and combined amiodarone and beta-blocker therapy. Clin Res Cardiol. 2008;97(1):56-60.
25. Paul G, Yusuf S, Sharma S. Unmasking of the Brugada syndrome phenotype during the acute phase of amiodarone infusion. Circulation. 2006;114(11):e489-491.
26. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trial. Eur Heart J. 2000;21(24):2071-2078.
27. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110(2):112-116.
28. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.
29. Lee KL, Hafley G, Fisher JD, et al. Effect of implantable defibrillators on arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Circulation. 2002;106(2);233-238.
30. Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation. 1997;96(9):2823-2829.
31. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation. 1999; 99(17):2268-2275.
32. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. JAMA. 2006;295(2): 165-171.
33. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657-2665.
34. Kuck K-H, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31-40.
35. Rakita U, Sobel SM, Mostow N, et al. Amiodarone pulmonary toxicity. Am Heart J. 1983;106(4):906-914.
36. Pollak PT, You YD. Monitoring of hepatic function during amiodarone therapy. Am J Cardiol. 2003;91(5):613-616.
37. Haffajee CI, Love IC, Canada AT, et al. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrythmias. Circulation. 1983:67(6):1347-1355.
38. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-798.
39. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91(6A):39D-44D.
40. Mattioni TA, Zheutlin TA, Sarmiento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med. 1989;111(7):574-580.
41. Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol. 1984;4(1):111-116.
42. Borders-Hemphill V. Concurrent use of statins and amiodarone. Consult Pharm. 2009;24(5):372-379.
43. Cushing DJ, Kowey PR, Cooper WD, et al. PM101: A cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol. 2009;607(1-3):167-172.
44. Kowey PR, Marinchak RA, Rials SJ, et al. Intravenous Amiodarone. J Am Coll Cardiol. 1997;29(6):1190-1198.
45. Antonelli D, Barzilay J. Acute thrombophlebitis following IV amiodarone administration. Chest. 1983;84(1);120b-120.
46. Tagliamonte E, Cice G, Ducceschi V, et al. Acute hepatitis following amiodarone administration. Minerva Cardioangiol. 1997; 45(9):451-456.
47. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-678.
48. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-2687.
49. Kessler D, Palepu N, Tustian A, et al. A novel amiodarone microemulsion injectable formulation. AAPS. Pharm Sci. 2002;4:W4122 (Abstract).
50. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90(8):853-859.
51. Kipp JE, Doty MJ, Rebbeck CL, Eilert JY, Inventors; Baxter International, assignee. Amiodarone-containing parenteral administration. United States patent US 6479541. 2002 November 12.
52. Elhasi S, Astaneh R, Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur J Pharm Biopharm. 2007;65:406-413.
53. Cushing DJ, Adams MP, Cooper WD, et al. Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol. 2009;49(4):407-415.
54. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008;36(1):30-42.
55. Prism Pharmaceuticals NDA for Captisol-enabled Amiodarone NDA; 2008 January.